Globus Medical (NYSE:GMED) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Posted by Stanley Muller on Nov 7th, 2026

Globus Medical (NYSE:GMED – Get Free Report) announced its earnings results on Thursday. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03, FiscalAI reports. The firm had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.51%. Globus Medical’s revenue was down .7% compared to the same quarter last year. During the same quarter last year, the business earned $1.18 earnings per share. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

Q3 revenue declined 0.7% to $763.7 million, as 3% growth in the base business excluding Nevro was offset by Nevro’s 25.7% decline. U.S. Spine grew 2%, held back by delayed product launches and lower-than-expected contributions from competitive recruiting.
Globus lowered its 2026 revenue outlook to $3.09 billion from $3.18 billion–$3.22 billion, citing Nevro weakness and limited contribution from new products this year. It reiterated non-GAAP EPS guidance of $4.95–$5.05.
Profitability and cash generation improved despite the revenue decline: non-GAAP EPS rose 4% to $1.23, adjusted gross margin expanded 140 basis points to 69.5%, and free cash flow reached a record $225 million.
Management expects new spine products—including SCRIPT, XLIF Prone, and eIQ—and greater robot and navigation pull-through to support growth in 2027 and beyond. Enabling Technologies revenue grew 24% in Q3, while deployed units rose 45% year over year.
The board authorized an additional $500 million share-repurchase program; Globus repurchased $142.9 million of shares in Q3. Management also expects continued margin improvement, while noting that higher R&D investment is planned.

Globus Medical Stock Down 13.2%

Shares of GMED stock traded down $10.77 during trading hours on Friday, hitting $70.67. 9,272,194 shares of the company were exchanged, compared to its average volume of 1,418,585. The firm has a fifty day moving average of $77.20 and a 200 day moving average of $83.18. Globus Medical has a 1 year low of $70.39 and a 1 year high of $101.40. The firm has a market cap of $9.49 billion, a PE ratio of 14.30, a PEG ratio of 1.14 and a beta of 0.98.

Insider Buying and Selling

In related news, Director James Tobin sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 60,000 shares of company stock valued at $4,838,400. Insiders own 18.38% of the company’s stock.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. UBS Group assumed coverage on Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target for the company. BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. Needham & Company LLC lowered their price objective on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. Finally, Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $96.92.

Get Our Latest Analysis on GMED

About Globus Medical

(Get Free Report)

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.